Want to join the conversation?
$BSX 2Q15 PR: Guidance 3Q15: Sales are expected to be in a range of $1.790-1.840Bil. On a GAAP basis, earnings per share are expected in the range of $0.10-0.13. Adjusted earnings, excluding acquisition, divestiture and restructuring-related net charges and amortization expense are estimated in a range of $0.21-0.23 per share.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.